marketshareAI

LungLife AI, Inc.

LLAIHealthcare
4.1500GBX
-2.35%
Market Cap
1.30M
Volume
15.25M
2704% of avg
P/E Ratio
EPS (TTM)
0
Beta
0.37
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p4.1500p16.4000p
4.1500p

Upcoming Events

31 August 2025
Circulogene to be able to provide the LungLB® test from its own laboratory
High Impact Event
Late Q3 2025
Deadline for Circulogene to exercise asset purchase option
High Impact Event
Q1 2025
Submission of application for Medicare coverage with MolDx
High Impact Event
LLAI
NEUTRAL

LungLife AI Provides Regulatory Update

The healthcare company provides an update on regulatory matters.

LLAI
NEUTRAL

LungLife AI Announces Change in Major Shareholding

The diagnostics company has announced a change in its major shareholding, with an investor increasing its stake.

LLAI
NEUTRAL

LungLife AI Announces Holding Changes

The healthcare diagnostics company has reported changes in major shareholdings.

LLAI
NEUTRAL

LungLife AI Announces Holding Change

The healthcare diagnostics company has announced a change in shareholding.

LLAI
NEUTRAL

LungLife AI Provides Regulatory Update

The healthcare company provides an update on regulatory matters.

LLAI
NEUTRAL

LungLife AI Announces Holding Change

The healthcare diagnostics company has reported a change in shareholding, with Cable Car Capital LLC now holding 5.3% of the voting rights.

LLAI
GOOD

LungLife AI Announces Proposed Cancellation of AIM Listing and Exclusive License Agreement with Circulogene

The diagnostics company has announced plans to cancel its AIM listing and enter an exclusive license agreement with a US-based liquid biopsy firm, providing financial support to continue operations.

LLAI
GOOD

LungLife AI Secures Exclusive US Distribution Deal for LungLB® Test

The diagnostics company has secured an exclusive US distribution deal for its LungLB® test, providing upfront payments, ongoing royalties, and a potential asset purchase option.

LLAI
NEUTRAL

LungLife AI Appoints New Nominated Adviser and Joint Broker

The diagnostic company announces the appointment of a new Nominated Adviser and Joint Broker, alongside its existing Joint Broker.

LLAI
BAD

LungLife AI Proposes AIM Cancellation Amid Funding Challenges

The diagnostic company is proposing to cancel its AIM listing after failing to secure a strategic partner or additional funding to commercialize its lung cancer test.